Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3Uveal Melanoma 2Melanoma 2Squamous Cell Carcinoma of the Lung 1Skin Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Interleukin-2 9Melphalan 8CTLA-4 Antigen 8sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7tebentafusp 6Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Bevacizumab 5aldesleukin 4aflibercept 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Blood Specimen Collection 4Biopsy 4trametinib 3sotrastaurin 3relatlimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Uveal Melanoma × glembatumumab vedotin × Clear all
NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡